A Randomised, Double-Blind, Placebo-Controlled Crossover Trial of Resveratrol Supplementation for Prophylaxis of Hormonal Migraine
Article
Article Title | A Randomised, Double-Blind, Placebo-Controlled Crossover Trial of Resveratrol Supplementation for Prophylaxis of Hormonal Migraine |
---|---|
ERA Journal ID | 211152 |
Article Category | Article |
Authors | Dzator, Jemima S. A., Howe, Peter R. C., Coupland, Kirsten G. and Wong, Rachel H. X. |
Journal Title | Nutrients |
Journal Citation | 14 (9) |
Article Number | 1763 |
Number of Pages | 12 |
Year | 2022 |
Publisher | MDPI AG |
Place of Publication | Switzerland |
ISSN | 2072-6643 |
Digital Object Identifier (DOI) | https://doi.org/10.3390/nu14091763 |
Web Address (URL) | https://www.mdpi.com/2072-6643/14/9/1763 |
Abstract | Resveratrol, a vasoactive phytoestrogen, has beneficial effects on cerebrovascular function. Previous research has shown that hormonal migraineurs have poorer cerebrovascular function than non-migraineur women. We aimed to investigate if resveratrol supplementation for three months could reduce the hormonal migraine burden index (HMBI: the number of days with menstrual migraine per month), reduce migraine-related disability and improve migraine-related quality of life. A randomised, double-blind, placebo-controlled, crossover, intervention trial was conducted in 62 hormonal migraineurs (mean age: 37.5 ± 0.8 years). Participants consumed 75 mg of resveratrol or matching placebo capsules twice daily for three months before crossing over to the other treatment arm. Participants completed a daily diary and the Headache Impact Test-6™, Migraine Disability Assessment and Migraine-Specific Quality of Life questionnaires at months 0, 3 and 6. The HMBI was the primary outcome and was calculated using data extracted from the participant’s diary. No differences in the HMBI (p = 0.895), the Headache Impact Test-6™, the Migraine Disability Assessment and Migraine-Specific Quality of Life were found between the resveratrol and placebo treatments. Resveratrol supplementation for three months did not affect the HMBI, the migraine-related disability or quality of life measures in our cohort of hormonal migraineurs. |
Keywords | resveratrol; phytoestrogen; migraine disability assessment; prophylaxis; hormonal migraine; cerebrovascular function; nutrient intervention |
ANZSRC Field of Research 2020 | 3006. Food sciences |
Byline Affiliations | University of Newcastle |
Centre for Health Research | |
University of Adelaide | |
Hunter Medical Research Institute, Australia |
https://research.usq.edu.au/item/z01y0/a-randomised-double-blind-placebo-controlled-crossover-trial-of-resveratrol-supplementation-for-prophylaxis-of-hormonal-migraine
Download files
51
total views18
total downloads1
views this month1
downloads this month